AbolerIS Pharma announces publication in Journal of Clinical Investigation on preclinical and translational data supporting use in Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy syndrome (APECED or APS-1).Read the press release from March 1, 2022
Our Approach
AbolerIS Pharma
Location: France, Pays de la Loire, Nantes
Member count: 1-10
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | Newton Bio... | newtonbioc... |
| - | Turenne Ca... | turennecap... |